1. Adams WP (2007) The High Five Process: tissue-based planning for breast augmentation. Plast Surg Nurs 27:197–201
2. Administration USFaD (2020) Breast implants—certain labeling recommendations to improve patient communication. Guidance for industry and food and drug administration staff
3. Administration USFaD (2013) Regulatory history of breast implants in the U.S. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/Breastlmplants/ucm064461.htm. Zugegriffen: 24. Nov. 2020
4. Administration USFaD (2018) Statement from Binita Ashar, M.D., of the FDA’s center for devices and radiological health on agency’s commitment to studying breast implant safety. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620589.htm;. Zugegriffen: 24. Nov. 2020
5. Administration USFaD (2019) Statement from FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., and Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health on FDA’s new efforts to protect women’s health and help to ensure the safety of breast implants. https://www.fda.gov/news-events/press-announcements/statement-fda-principal-deputy-commissioner-amy-abernethy-md-phd-and-jeff-shuren-md-jd-director-fdas. Zugegriffen: 20. Nov. 2020